Merck did it.
In one of the most intense commercial and research development rivalries in biopharma history, Merck’s Keytruda has edged ahead of Bristol-Myers Squibb’s Opdivo for the first time since the showdown got started nearly 4 years ago.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,